2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMORecruiting
to investigate (1) the additional effect of tDCS on language and communication, when administered during aphasia therapy in the sub-acute phase post stroke (2) its cost-effectiveness, (3) its effect on neural reorganisation of language, and (4) the…